步长制药: 山东步长制药股份有限公司第五届监事会第七次会议决议公告

Core Points - The company held its seventh meeting of the fifth supervisory board on August 27, 2025, with all four supervisors present, ensuring compliance with legal and regulatory requirements [1] - The supervisory board reviewed and approved the 2025 semi-annual report, confirming that the report's preparation and review processes adhered to relevant laws and internal management systems [1] - The report was deemed to accurately reflect the company's operational and financial status for the first half of 2025, with no confidentiality breaches identified among the personnel involved in its preparation [1] Fund Management - The company prepared a special report on the storage and actual use of raised funds for the first half of 2025, in accordance with relevant laws and regulations [2] - The supervisory board unanimously approved the report, with all four votes in favor and none against or abstaining [2] Profit Distribution - The company proposed a profit distribution plan for the first half of 2025 to enhance investor returns and boost shareholder confidence, which does not require shareholder meeting approval based on the authorization from the 2024 annual general meeting [3] - The profit distribution plan was also unanimously approved by the supervisory board [3]